DDReg pharma

DELIVER BETTER DATA TO ENSURE FASTER APPROVAL
DDReg Pharma

Regulatory

challenges and Opportunities in Veterinary Regulations

Navigating Challenges and Future Opportunities in Veterinary Regulations

The field of veterinary medicine is rapidly advancing, driven by new therapies and technologies as well as increasing public health concerns about antimicrobial resistance (AMR). Regulatory agencies around the world–such as FDA, EMA and regional bodies–are adapting quickly to these changes, with regulatory frameworks constantly adapting to ensure veterinary medicinal products (VMPs) meet stringent safety […]

Navigating Challenges and Future Opportunities in Veterinary Regulations Read More »

Malaysia Pharmaceutical Regulatory Pathway

Understanding the Pharmaceutical Regulatory Landscape of Malaysia

Malaysia’s pharmaceutical industry is a rapidly growing sector, driven by increasing healthcare demands, advancements in medical research, and government support. For pharmaceutical companies looking to enter the Malaysian market, understanding the regulatory framework is crucial. The National Pharmaceutical Regulatory Agency (NPRA) plays a key role in overseeing drug approvals, quality standards, and compliance with national

Understanding the Pharmaceutical Regulatory Landscape of Malaysia Read More »

Registered Products in USA through Pharma Regulatory Consultant

How Pharmaceutical Regulatory Consultant Helps Product Registration in the USA

The pharmaceutical regulatory consultants are specialists in FDA regulations and can guide companies through the registration process for their products making sure that all the required documentation, clinical data, and measures to ensure compliance are in the correct order. Over the decades, the regulatory framework in the United States has advanced and driven by scientific

How Pharmaceutical Regulatory Consultant Helps Product Registration in the USA Read More »

PRIME vs. EU pathways: Strategy, global impact, and drug development insights

Comparing PRIME and EU Pathways: Long -Term Strategy and Global Impact

In the European Union (EU), the European Medicines Agency (EMA) has implemented several expedited regulatory pathways, notably the PRIority MEdicines (PRIME) scheme, to facilitate the development and approval of promising medicines. Launched in March 2016, the PRIME scheme aims to enhance support for the development of medicines that target an unmet medical need. In addition

Comparing PRIME and EU Pathways: Long -Term Strategy and Global Impact Read More »

impact of vitro diagnostic medical device regulation in EU

Understanding the Impact of IVDR on Precision Medicine Development in the EU

The European Union introduced the In Vitro Diagnostic Regulation (IVDR), an elaborate regulatory framework intended to increase safety, performance and reliability of in vitro diagnostic (IVD) medical devices. Replacing its predecessor (IVDD), EU IVDR requires stricter requirements for compliance while placing greater emphasis on clinical evidence, risk classification and post market surveillance. Precision medicine, an innovative

Understanding the Impact of IVDR on Precision Medicine Development in the EU Read More »

Current Trends patient engagement in healthcare

Patient Engagement in Healthcare: Current Trends and Future Opportunities

For years, the focus of healthcare development and delivery has been on treatment and outcomes, often with limited input from patients. However, there is now a growing recognition that patients should not just be passive recipients of care—they should be active participants in their own healthcare journey. This patient-centered approach is transforming the way drugs

Patient Engagement in Healthcare: Current Trends and Future Opportunities Read More »

Collaborating for Global Success in Advanced Therapy Medicinal Products (ATMPs)

Advanced Therapy Medicinal Products (ATMPs) are transforming the medical landscape, offering revolutionary treatments for diseases that previously lacked effective solutions. These products include cutting-edge innovations such as gene therapies, somatic cell therapies, and tissue-engineered products. Despite their potential, ATMPs face numerous challenges—scientific, regulatory, logistical, and financial—that hinder their development and global market access. Addressing these

Collaborating for Global Success in Advanced Therapy Medicinal Products (ATMPs) Read More »

personalized drug in development

Navigating the Challenges of Personalized Medicine in Development

The landscape of modern medicine is undergoing a revolutionary transformation, with personalized medicine at the forefront. As we move away from the “one-size-fits-all” approach and embrace treatments tailored to individual genetic profiles, lifestyle, and environmental factors, the potential to improve patient outcomes has never been greater. However, this evolution also comes with unique challenges, particularly

Navigating the Challenges of Personalized Medicine in Development Read More »

Role of Real-World Evidence in Post-Marketing Safety

Leveraging Real-World Evidence to Enhance Post-Marketing Safety Globally

Real-World Evidence (RWE) refers to clinical evidence regarding the usage and potential benefits or risks of a medical product, derived from the analysis of Real-World Data (RWD). RWD encompasses information collected from various sources, including electronic health records (EHRs), insurance claims, patient registries, and data from mobile health applications. This evidence is crucial in understanding

Leveraging Real-World Evidence to Enhance Post-Marketing Safety Globally Read More »

artificial intelligence in drug development and drug discovery

Regulatory Challenges and Opportunities with AI in Drug Development

AI has emerged as a transformative force in drug development, promising to revolutionize how new therapies are discovered, tested, and brought to market. AI technologies are revolutionizing the pharmaceutical landscape. From hastening identification of potential drug candidates, to optimizing clinical trial designs and post-market surveillance – AI technologies are revolutionizing pharmaceutical innovation. AI technologies allow

Regulatory Challenges and Opportunities with AI in Drug Development Read More »